Anthony E. Boitano

机构：Fate Therapeutics (United States), Casma Therapeutics (United States), Vertex Pharmaceuticals (United States)

发表论文 92 篇 · 总被引 3205 次 · h-index 18

代表论文

• Effective Multi-lineage Engraftment in a Mouse Model of Fanconi Anemia Using Non-genotoxic Antibody-Based Conditioning (2020 · Molecular Therapy — Methods & Clinical Development · 被引 33)
• A Single Dose of CD117 Antibody Drug Conjugate Enables Autologous Gene-Modified Hematopoietic Stem Cell Transplant (Gene Therapy) in Nonhuman Primates (2019 · Blood · 被引 17)
• Clearing and replacing tissue-resident myeloid cells with an anti-CD45 antibody–drug conjugate (2023 · Blood Advances · 被引 11)
• A Single Dose of a Novel Anti-Human CD117-Amanitin Antibody Drug Conjugate (ADC) Engineered for a Short Half-Life Provides Dual Conditioning and Anti-Leukemic Activity and Extends Survival Compared to Standard of Care in Multiple Preclinical Models of Acute Myeloid Leukemia (AML) (2020 · Blood · 被引 8)
• A Novel Targeted Approach to Achieve Immune System Reset: CD45-Targeted Antibody Drug Conjugates Enable Autologous HSCT, Ameliorate Disease in Autoimmune Models, Potently Kill Human Immune Cells from Normal Donors and MS Patients, and Achieve Immune Depletion in Non-Human Primates (NHP) (2019 · Blood · 被引 5)
• Mgta-456, an Aryl Hydrocarbon Receptor (AHR) Antagonist Based Expansion of CD34+ Hematopoietic Stem Cells (HSC), Permits Selection of Better HLA Matched Cord Blood Units (CBUs) and Promotes Faster Neutrophil Recovery and Uniform Engraftment with Potentially Less Acute Graft-Vs-Host Disease (GVHD) (2019 · Blood · 被引 4)